Company profile
Sanofi
NASDAQ:SNYBiotechnology: Pharmaceutical Preparations
Drug pipeline (166)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Acetaminophen | approved | — | 78 | approved |
| Aflibercept | approved | — | 11 | approved |
| Aluminum hydroxide | approved | — | 0 | — |
| AMBENONIUM CHLORIDE | approved | — | 0 | — |
| Aspirin | approved | — | 25 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2104)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00046150 | phase3 | completed | 2002-05-01 | — | Sanofi | 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. |
| NCT00103649 | phase3 | completed | 2003-11-01 | 2007-10-01 | Sanofi | 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type |
| NCT00563225 | phase3 | completed | 2002-10-01 | — | Sanofi | 20 Week Bridging Study in Type II DM |
| NCT00976937 | phase3 | completed | 2009-08-01 | 2011-03-01 | Sanofi | 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years |
| NCT00975286 | phase3 | completed | 2009-10-01 | 2011-08-01 | Sanofi | 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine |
FDA applications (193)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| ANDA 061596 | ANDA | SANOFI AVENTIS US LLC | ||||
Loading… | ||||||
| ANDA 061613 | ANDA | SANOFI AVENTIS US LLC | ||||
Loading… | ||||||
| ANDA 061876 | ANDA | SANOFI AVENTIS US LLC | ||||
Loading… | ||||||
| ANDA 061884 | ANDA | SANOFI AVENTIS US LLC | ||||
Loading… | ||||||
| ANDA 062659 | ANDA | SANOFI AVENTIS US LLC | ||||
Loading… | ||||||